Bafiertam
Active Ingredient(s): Monomethyl FumarateFDA Approved: * April 28, 2020
Pharm Company: * BANNER LIFE SCIENCES
Category: Multiple Sclerosis
Monomethyl fumarate, sold under the brand name Bafiertam is a medication for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[1] It is taken by mouth. The most common adverse reactions are flushing, abdominal pain, diarrhea, and nausea.[1] It was approved for medical use in the United States in April 2020.[2][... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.